August 10, 2017
Sponsored by Kaneka
Recent improvements in monoclonal antibody (MAb) upstream process technologies have led to increased product titers (from 5 to 10 g/L) and a corresponding change in impurity levels. To yield highly pure MAb drugs from such high-titer feedstocks, new, robust, and cost-effective purification processes need to be developed to follow this upward trend.
KANEKA has developed KANEKA KanCapA™ 3G, an innovative protein A resin that demonstrates higher binding capacities and allows milder elution conditions than well-known high-binding capacity agarose based resin.
Login to read the full PDF of the application note.
You May Also Like
